Low Dose Intravenous (IV) Infusion of BNP in the Presence and Absence of Acute Type V Phosphodiesterase (PDE V) in Improving Renal Function in Hospitalized Chronic Heart Failure (CHF) Patients With Renal Dysfunction

Phase 1/2 Completed 60 enrolled Mayo Clinic National Institutes of Health (NIH) · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to determine if low doses of BNP can improve renal function in people with chronic heart failure with renal dysfunction, also to determine whether Sildenafil assists with improvement. This study will enroll only hospitalized patients with heart failure.

Timeline

Start: 2009-10
Primary completion: 2019-06
Completion: 2019-12

Publications

Hubers SA, Benike SL, Johnson BK, McKie PM, Scott C, Chen HH. Renal Effects of Combination Phosphodiesterase V Inhibition and Low-Dose B-Type Natriuretic Peptide in Acute Heart Failure: A Randomized Clinical Trial. Circ Heart Fail. 2024 Dec;17(12):e011761. doi: 10.1161/CIRCHEARTFAILURE.124.011761. Epub 2024 Nov 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Nesiritide	Protein / enzyme biologic	0.005 ug/kg	Intravenous
Comparator	Sildenafil	Unknown	12.5 mg	—

Low Dose Intravenous (IV) Infusion of BNP in the Presence and Absence of Acute Type V Phosphodiesterase (PDE V) in Improving Renal Function in Hospitalized Chronic Heart Failure (CHF) Patients With Renal Dysfunction

Summary

Timeline

Publications

Drugs

Indications